5-hydroxytryptophan has been researched along with Friedreich Ataxia in 5 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Friedreich Ataxia: An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 7.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 5.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "18 patients with degenerative cerebellar ataxia were given for 12 months, high doses of D-L-5 Hydroxytryptophan (16 mg/kg/day) with a peripheral inhibitor of 5-HTP Decarboxylase." | 5.26 | [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. ( Adeleine, P; Garde, A; Robert, JM; Trouillas, P, 1981) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 3.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 1.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "18 patients with degenerative cerebellar ataxia were given for 12 months, high doses of D-L-5 Hydroxytryptophan (16 mg/kg/day) with a peripheral inhibitor of 5-HTP Decarboxylase." | 1.26 | [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. ( Adeleine, P; Garde, A; Robert, JM; Trouillas, P, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trouillas, P | 3 |
| Garde, A | 1 |
| Robert, JM | 1 |
| Adeleine, P | 1 |
| Serratrice, G | 1 |
| Laplane, D | 1 |
| Rascol, A | 1 |
| Augustin, P | 1 |
| Barroche, G | 1 |
| Clanet, M | 1 |
| Degos, CF | 1 |
| Desnuelle, C | 1 |
| Dumas, R | 1 |
| Botez, MI | 1 |
| Mayer, P | 1 |
| Bellemare, F | 1 |
| Couture, J | 1 |
| Rohmer, F | 1 |
| Warter, JM | 1 |
| Coquillat, G | 1 |
| Maitrot, D | 1 |
| Kurtz, D | 1 |
| Micheletti, G | 1 |
| Mack, G | 1 |
| Mandel, P | 1 |
2 trials available for 5-hydroxytryptophan and Friedreich Ataxia
| Article | Year |
|---|---|
Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Double-Blind Method; Female; Friedreich Ataxia; Humans; Male | 1995 |
[Pharmacological and biochemical approach to a syndrome of action and intention myoclonus in the course of degenerative disease of the nervous system].
Topics: 5-Hydroxytryptophan; Adult; Benzazepines; Cerebellar Ataxia; Clinical Trials as Topic; Diagnosis, Di | 1973 |
3 other studies available for 5-hydroxytryptophan and Friedreich Ataxia
| Article | Year |
|---|---|
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich | 1984 |
[Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
Topics: 5-Hydroxytryptophan; Adult; Benserazide; Cerebellar Ataxia; Female; Friedreich Ataxia; Humans; Male; | 1981 |
Can we treat respiratory failure in Friedreich ataxia?
Topics: 5-Hydroxytryptophan; Adult; Amantadine; Dopamine Agents; Friedreich Ataxia; Humans; Male; Respirator | 1997 |